160 related articles for article (PubMed ID: 2118328)
1. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
Parent M; St-Laurent M; LeBel M
Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
[TBL] [Abstract][Full Text] [Related]
2. Influence of lomefloxacin on the pharmacokinetics of theophylline.
LeBel M; Vallée F; St-Laurent M
Antimicrob Agents Chemother; 1990 Jun; 34(6):1254-6. PubMed ID: 2393286
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
4. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
5. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
6. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
7. Renal tolerance of fleroxacin in healthy volunteers.
Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
Wolfhagen MJ; Hoepelman AI; Verhoef J
Antimicrob Agents Chemother; 1990 Mar; 34(3):409-12. PubMed ID: 2110437
[TBL] [Abstract][Full Text] [Related]
9. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.
Bowie WR; Willetts V; Jewesson PJ
Antimicrob Agents Chemother; 1989 Oct; 33(10):1778-82. PubMed ID: 2511802
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Panneton AC; Bergeron MG; LeBel M
Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
[TBL] [Abstract][Full Text] [Related]
11. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
[TBL] [Abstract][Full Text] [Related]
12. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
16. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
17. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Frankenschmidt A; Naber KG; Bischoff W; Kullmann K
J Urol; 1997 Oct; 158(4):1494-9. PubMed ID: 9302150
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
19. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.
Whitby M; Angus L; Nimmo G; Hill V
Chemotherapy; 1996; 42(6):468-72. PubMed ID: 8957583
[TBL] [Abstract][Full Text] [Related]
20. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
Kees F; Naber KG; Schumacher H; Grobecker H
Chemotherapy; 1988; 34(6):437-43. PubMed ID: 2468456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
